Business
Puma Biotechnology Reports First Quarter 2026 Financial Results
LOS ANGELES, May 07, 2026--Puma Biotechnology hosted a conference call and provided a corporate update on May 7, 2026, following release of its 1Q-2026 financial results.
About this update from Puma Biotechnology Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":800,"url":"https://media.zenfs.com/en/business-wire.com/df325d2078e6e0a2f27d0db842fc4abd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QGCJnknEpBmAkkqHTO4ifw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/df325d2078e6e0a2f27d0db842fc4abd","width":960,"height":320},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/W5G.Gjzms07DTgJc8wYaMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIxMw--/https://media.zenfs.com/en/business-wire.com/df325d2078e6e0a2f27d0db842fc4abd","width":640,"height":213},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FdJxtudUR8oXyYACYbKz6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA-/https://media.zenfs.com/en/business-wire.com/df325d2078e6e0a2f27d0db842fc4abd","width":1200,"height":400}},"lazy":false},{"type":"text","content":"Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, May 07, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025.","length":293,"tagName":"p"},{"type":"text","content":"Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the first quarter of 2026 was $42.0 million, compared to product revenue, net of $43.1 million in the first quarter of 2025.","length":255,"tagName":"p"},{"type":"text","content":"Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss of $3.8 million, or $0.07 per basic and diluted share, for the first quarter of 2026, compared to net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 2025.","length":298,"tagName":"p"},{"type":"text","content":"Non-GAAP adjusted net loss was $1.9 million, or $0.04 per basic and diluted share, for the first quarter of 2026, compared to non-GAAP adjusted net income of $5.0 million, or $0.10 per basic and diluted share, for the first quarter of 2025. Non-GAAP adjuste...